Edition:
United Kingdom

People: Novavax Inc (NVAX.OQ)

NVAX.OQ on NASDAQ Stock Exchange Global Select Market

2.48USD
12 Dec 2018
Change (% chg)

-- (--)
Prev Close
$2.48
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
1,406,286
52-wk High
$2.75
52-wk Low
$1.05

Glenn, Gregory 

Dr. Gregory M. Glenn M.D., is President, Research and Development of Novavax, Inc. Previously served as Senior Vice President, Research and Development since January 2014, as Senior Vice President, Chief Medical Officer from January 2011 to January 2014, and Senior Vice President and Chief Scientific Officer from June 2010 to January 2011. Prior to joining the Company, Dr. Glenn was the Chief Scientific Officer and founder of Iomai Corporation, which was acquired in 2008 by Intercell AG, an associate in international health at Johns Hopkins University’s School of Public Health and a clinical and basic research scientist at Walter Reed Army Institute of Research. Dr. Glenn received a B.A. in biology and chemistry from Whitman College and a M.D. from Oral Roberts University School of Medicine. He also completed the Medical Research Fellowship at the Walter Reed Army Institute of Research.

Basic Compensation

Total Annual Compensation, USD 679,500
Restricted Stock Award, USD --
Long-Term Incentive Plans, USD --
All Other, USD 541,750
Fiscal Year Total, USD 1,221,250

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --
Name Fiscal Year Total

James Young

533,780

Stanley Erck

2,771,680

John Trizzino

947,747

Gregory Glenn

1,221,250

John Herrmann

913,317

Jody Lichaa

--
As Of  31 Dec 2017